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Abstract
Background The clinical effect of stent treatment has
been evaluated by mainly physicians; only a limited
number of prospective studies have used patient-reported
outcomes for this purpose. The aim of this work was to
study the clinical effect of self-expanding metal stents in
treatment of malignant gastrointestinal obstructions, as
evaluated by patient-reported outcomes, and compare the
rating of the treatment effect by patients and physicians.
Methods Between November 2006 and April 2008, 273
patients treated with SEMS for malignant GI and biliary
obstructions were recruited from nine Norwegian hospitals.
Patients and physicians assessed symptoms independently
at the time of treatment and after 2 weeks using the
European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 questionnaire supplemented
with speciﬁc questions related to obstruction.
Results A total of 162 patients (99 males; median
age = 72 years) completed both assessments and were
included in the study. A signiﬁcant improvement in the
mean global health score was observed after 2 weeks (from
9 to 18 on a 0–100 scale, P\0.03) for all stent locations.
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DOI 10.1007/s00464-011-1680-7Both patients and physicians reported a signiﬁcant reduc-
tion in all obstruction-related symptoms ([20 on the 0–100
scale, P\0.006) after SEMS treatment. The physicians
reported a larger mean improvement in symptoms than did
the patients, mainly because they reported more severe
symptoms before treatment.
Conclusion SEMS treatment is effective in relieving
symptoms of malignant GI and biliary obstruction, as
reported by patients and physicians. The physicians, how-
ever, reported a larger reduction in obstructive symptoms
than did the patients. A prospective assessment of patient-
reported outcomes is important in evaluating SEMS
treatment.
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Quality of life
Palliative treatment with self-expanding metal stents
(SEMS) is regarded as a safe and highly effective proce-
dure for relief of symptoms caused by malignant obstruc-
tions of the gastrointestinal (GI) tract [1–8]. Most studies
concerning treatment with SEMS, whether randomized,
comparative, or merely descriptive, focus on technical
success (e.g., correct deployment of the stent), clinical
success (restored passage), procedure-related complica-
tions, and cost-effectiveness. Typically, the clinical out-
comes of SEMS treatment have been evaluated by the
physician [9]; only a few prospective studies reported
repeated symptom assessments by the patient [10–16].
Since patients’ and physicians’ ratings of treatment effects
do not always correspond well, palliative treatment efforts
such as SEMS for malignant GI obstructions should be
evaluated by individual outcome measures reported by the
patients as well as by the physicians [17–22].
The main objective of this multicenter study was to use
patient-reported outcomes to evaluate the treatment effects
of SEMS on quality of life (QoL) and symptoms related to
malignant GI and biliary obstruction. An additional aim of
the study was to compare patient- and physician-reported
evaluations of the treatment’s effects.
Materials and methods
Nine Norwegian hospitals performing SEMS treatment for
GI obstructions participated in the present study. The
inclusion period was from November 2006 to April 2008.
Patients were eligible for consecutive inclusion according
to the following criteria: (1) symptoms related to malignant
GI obstruction, (2) indication for treatment with all types of
metal stents established, (3) ﬂuency in oral and written
Norwegian, and (4) cognitive capability to complete the
questionnaires. Patients who received their colonic stent as
a ‘‘bridge to surgery’’ (i.e., to relieve the acute obstruction
prior to elective surgery) and underwent bowel resection
within 2 weeks after stent placement were not asked to
complete the questionnaire after 2 weeks and were thus not
included in the analyses. The study was approved by the
Regional Committee for Medical Research Ethics in
Southern Norway and the Data Protection Supervisor at
Oslo University Hospital, Ulleva ˚l. All patients received
oral and written information about the study. Written
informed consent was obtained from all participants.
Stent procedure
All stents were deployed endoscopically under ﬂuoroscopic
guidance. Both covered and uncovered stents were used for
esophageal and biliary stent treatment, while uncovered
stents were used in other locations.
Assessment of patient-reported outcomes
The European Organisation for Research and Treatment of
Cancer Core Quality of Life Questionnaire, EORTC QLQ-
C30, version 3.0 [23], was used to assess patient-reported
outcomes, supplemented with selected questions from
other relevant EORTC organ- and disease-speciﬁc modules
(http://www.eortc.be/). The EORTC QLQ-C30 is a cancer-
speciﬁc 30-item self-reporting questionnaire consisting of
both multi-item scales and single-item measures. These
include ﬁve functional scales (i.e., physical, role, cognitive,
emotional, and social), three symptom scales (i.e., fatigue,
nausea/vomiting, and pain), and six single items (i.e.,
dyspnea, insomnia, appetite loss, constipation, diarrhea,
and ﬁnancial problems), as well as two questions where the
patients assessed their overall health and QoL on a scale
from 1 to 7. Combining these two scores resulted in a
global health score.
EORTC recommends that organ-speciﬁc modules be
used in addition to the core questionnaire to capture diag-
nosis- or treatment-speciﬁc problems. For the purpose of the
present study, a selection of questions was made from the
relevant organ-speciﬁc modules to reduce the respondent’s
burden and to focus on speciﬁc problems pertaining to the
different diagnostic or stent groups. Questions to be
answered by the patients receiving esophageal, biliary, and
colonic stents were selected from the stomach module
EORTC QLQ-STO22 [24], the pancreatic module EORTC
QLQ-PAN26 [25], and the colorectal module EORTC
QLQ-CR38 [26], respectively (Table 2). Patients who
received gastroduodenal stents did not answer any
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symptoms, nausea and vomiting, were speciﬁcally addres-
sed by the core questionnaire.
Higher scores on the symptom scales and single items
from the core questionnaires and the organ-speciﬁc mod-
ules indicated more severe symptoms, while higher scores
on the functional scales indicate better functioning. All
items were to be answered on an ordinal scale ranging from
1 (‘‘Not at all’’) to 4 (‘‘Very much’’), except for the two
modiﬁed visual analog scales assessing global health and
QoL; they ranged from 1 to 7. The time frame was the past
7 days. Scale and item scores were transformed into a
continuous scale from 0 to 100, as described in the EORTC
Scoring Manual [27]. A mean score difference of 5–10 is
usually regarded as a small but clinically noticeable change
for the patients, a change between 10–20 as moderate, and
[20 as a large clinical change [28, 29].
Administration of questionnaires
All assessments were performed twice, at inclusion (-2
to ?1 day before/after the procedure) and 2 weeks after
treatment. The questionnaire was administered to the
study participants upon admission by the treating physi-
cian or a study nurse. The same questionnaire was given
to the patients when leaving the hospital. The patients
were instructed to complete the second questionnaire
2 weeks after stent treatment and return it by mail. The
2-week time span between assessments was chosen to
reach the maximum effect of the stent treatment and
reduce the impact of disease progression. To reduce the
inﬂuence of recall bias, the patients had to complete the
initial questionnaire no later than the day after the pro-
cedure and the second questionnaire no later than 3 weeks
after treatment. The physicians assessed the same organ-
speciﬁc symptoms at inclusion and the second assessment
at hospital discharge or 2 weeks after stent treatment if
the patient was still hospitalized. The same physician was
responsible for the before and after assessment of
symptoms.
Statistical analysis
Power calculations were based on a mean change of 10
with a standard deviation (SD) of 15 of global health,
with 90% power and a 5% level of signiﬁcance, which
yielded a sample size of 26 patients in each of the
treatment groups for the four stent locations. Wilcoxon
signed-rank test with 5% signiﬁcance level was used
when evaluating changes of symptoms before and after
treatment. Statistical analyses were performed using SPSS
16.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
A total of 273 patients were eligible for inclusion in the
study, varying from 2 to 105 patients at the nine partici-
pating centers. Two hundred thirty-eight (87%) patients
completed the questionnaire prior to the stent procedure,
and 162 (68%) of these completed both questionnaires.
Twenty-seven patients did not return the second form for
unknown reasons (Fig. 1). Ninety-nine males and 63
females with a median age of 72 years were included.
Clinical and demographic characteristics are given in
Table 1. The most frequent diagnoses were cancer of the
colon and pancreas. Of the 18 patients with gastric cancer
who received stents, eight had obstructions located in the
cardia ventriculi and were treated with esophageal stents.
Ten patients had gastric outlet obstruction and were treated
with duodenal stents.
Patient-reported outcomes
Patients reported a clinically and statistically signiﬁcant
reduction in all obstruction-related symptoms in all four
stent locations, with a mean reduction of at least 20
(P\0.02). Furthermore, a clinically and statistically sig-
niﬁcant improvement in global health function (P\0.03)
was observed in all treatment groups. Additionally, various
other symptoms improved signiﬁcantly: nausea/vomiting
(colon and biliary), appetite loss (biliary and gastroduo-
denal), pain (gastroduodenal and colonic), and constipation
(colonic) (Tables 2, 3, 4, and 5). The total numbers of
patients experiencing symptomatic improvement C 20,
improvement\20, or worsening are reported in Table 6.
The scorings from patients who completed the pre-
treatment questionnaire before treatment were similar to
those from patients who completed it the day after treat-
ment. Sixty-four patients (40%) completed the ﬁrst
assessment the day after stent insertion because of emer-
gency stent treatment or pronounced symptoms before
treatment. The rate of missing items was low, 0.9 and 1.0%
in the two assessments, respectively. For the multi-items
scales, missing values were assigned according to a stan-
dard scoring procedure (EORTCs scoring manual, [27]) by
replacing missing items with the scale mean values, pro-
vided that half or more of the scale items were completed.
Comparison of symptoms evaluated by patients
and physicians
When comparing the patients’ and physicians’ scores, a
signiﬁcant difference in the answers of six of seven
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cians indicated symptoms as more pronounced than the
patients (P\0.02). However, when comparing the post-
treatment evaluation, the scores tended to be similar (a
statistically signiﬁcant difference was found for two
questions, see Table 7). When evaluating the clinical effect
as an improvement in obstructive symptoms, the physicians
reported a larger mean reduction in obstructive symptoms
and, thus, a better treatment effect as compared to the
patients.
The median hospital stay was 4 days (range = 0–64).
Therefore, physicians completed their second symptom
assessment\7 days after the ﬁrst registration in (131/162)
81% of the cases. The patients completed their second
assessment of symptoms after 2 weeks (assessing symp-
toms between days 7 and 14).
Short-term outcome/complications
During the ﬁrst week, 12 of 162 patients (7%) experienced
complications: three nonfunctional stents, two stent migra-
tions, two bleeding episodes, two episodes of cholangitis,
one tracheal-esophageal ﬁstula, one stent obstruction by
food impaction, and one stent obstruction by tumor over-
growth. There was no procedure-related mortality.
Discussion
This study is one of very few that evaluates the symp-
tomatic effect of palliative GI stenting based on patient-
reported outcomes. Furthermore, to our knowledge it is the
ﬁrst to compare patients’ and physicians’ assessments of
the symptomatic effect of SEMS treatment. The present
study demonstrates that the majority of patients found
treatment with SEMS effective in relieving obstructive
symptoms in all GI tract locations. Additionally, patients
reported a signiﬁcant clinical improvement in global health
after 2 weeks for all four stent locations. The physicians
tended to evaluate pretreatment symptoms as more severe
than did the patients. The postprocedure scorings were
more similar.
This study shows that treatment with SEMS is effective
in relieving symptoms related to malignant GI obstruction.
Fig. 1 Flowchart showing the selection of the 162 patients included in this study
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study were treated at small local centers, not large expert
centers. SEMS as palliative principle seems to be effective
independent of location. With regard to the symptomatic
effect on esophageal and gastric outlet obstructions,
our ﬁndings are in accordance with previous studies.
Additionally, were we able to ﬁnd signiﬁcantly improved
general well-being and better QoL, which most previous
studies had not been able to document [10, 12]. A study of
colon obstruction using patient-reported outcomes ended
early and was therefore not able to make a conclusion [30].
That physicians’ and patients’ perceptions of symptoms
differ is in line with previous studies in palliative medicine
that compared physicians and patients, although underes-
timation of patients’ symptoms by physicians is more
common [17–21]. We do not know the reasons for the
discrepancies in scoring found in our study; but one plau-
sible explanation may reﬂect the enthusiasm of the physi-
cians performing these procedures and their needs to justify
the indication. The study was not designed to clarify this
question.
Table 1 Clinical and demographic characteristics of 162 patients
treated by self-expanding metal stents for malignant gastrointestinal
obstruction
Age [median (range)] 72 (33–93)
Gender M/F 99/63
Survival [median (range)] (days) 111 (15–535)
Diagnoses
Colon cancer 49 (30%)
Pancreatic cancer 41 (25%)
Gastric cancer 18 (11%)
Esophageal cancer 28 (17%)
Bile duct cancer 9 (6%)
Other malignancies
a 17 (11%)
Other palliative treatment
Chemotherapy (during day 0–14) 18 (11%)
Radiotherapy (during day 0–14) 7 (4%)
Stent locations
Esophageal 41 (25%)
Gastroduodenal 33 (20%)
Biliary 40 (25%)
Colon 48 (30%)
a Breast cancer, n = 1, lymphoma, n = 1; lung cancer, n = 3;
prostate cancer, n = 2; hepatocellular carcinoma, n = 1; gallbladder
cancer, n = 1; thyroid cancer, n = 1; papillary cancer, n = 1; ovar-
ian cancer, n = 3; duodenal cancer, n = 1; malignant melanoma,
n = 2
Table 2 Scores from EORTC C30
a and selected obstruction-related questions from EORTC OES 18 given by 41 patients treated with
esophageal stents
Before After Difference P value
Global health function
b 30.0 (18.0) 39.1 (26.1) 9.2 (26.4) 0.03
Symptom scales
a,c
Nausea/vomiting 37.8 (31.0) 33.7 (31.7) 4.1 (39.6) 0.49
Pain 43.5 (29.6) 51.2 (31.5) -7.7 (34.6) 0.20
Single items
c
Appetite loss 69.1 (38.3) 61.8 (39.1) 7.3 (41.8) 0.31
Organ-speciﬁc questions from EORTC OES 18
c
Have you had problems eating solid food? 86.8 (26.3) 51.0 (40.1) 36.0 (51.6) \0.001
Have you had problems eating liquidized or soft food? 63.1 (35.3) 30.0 (37.3) 32.4 (52.3) 0.001
Have you had problems drinking liquids? 38.6 (36.8) 16.7 (26.5) 22.0 (41.2) 0.002
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of functioning
c Scale from 0 to 100; high scores represent more severe symptoms
Table 3 EORTC C30
a results from 33 patients treated with gastro-
duodenal stents
Before After Difference P value
Global health
function
b
22.0 (19.3) 38.4 (26.4) 16.4 (24.8) \0.001
Symptom scales
b
Pain 57.6 (28.6) 39.9 (36.3) 17.7 (36.3) 0.014
Nausea/vomiting 63.1 (31.1) 30.3 (27.5) 32.8 (38.7) \0.001
Single items
b
Appetite loss
c 81.8 (25.1) 65.7 (37.7) 16.2 (34.5) 0.013
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was
made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent more severe symptoms
c Scale from 0 to 100; high scores represent higher level of overall
functioning
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earlier than the patients (earlier than day 7 for 81% of the
patients). The study protocol did not include a scheduled
follow-up after stent treatment. The patients were often
severely ill, with long travelling distance to hospital, and an
extra hospital visit to allow the physician to perform a
symptom assessment was hence not included in the follow-
up. As the hospital stay related to the stent procedure
usually was of short duration, the physicians’ scoring often
had to be performed at discharge from hospital. However,
it is likely that the questionnaire’s 1-week time format
reduced the inﬂuence of the discrepancy of when the
physicians and patients did the second assessment.
Although there were signiﬁcant improvements for the
group in total, there was interindividual variation and some
patients did not experience improvement in their obstruc-
tive symptoms. A review of the medical charts revealed
that absence of symptomatic improvement often could be
explained by dysfunctional stents, migrations, infections,
pain, or intercurrent diseases during the ﬁrst 2 weeks. This
represented a limited number of patients and separate
subanalyses were not performed. Furthermore, ongoing
treatment with other modalities (e.g., chemotherapy) can
potentially inﬂuence symptom scoring negatively. We
found no signiﬁcant difference in the scorings of the 25
patients who received chemo- and/or radiation therapy
during the assessment period.
Table 4 Scores from EORTC C30
a and selected obstruction-related
questions from EORTC PAN26 from 40 patients treated with biliary
stents
Before After Difference P value
Global health
function
b
30.4 (25.9) 48.3 (28.0) 17.9 (34.3) 0.003
Symptom scales
c
Pain 48.3 (36.2) 28.8 (25.0) 19.6 (31.8) 0.001
Nausea/vomiting 35.0 (30.8) 21.3 (23.3) 13.8 (28.7) 0.005
Single items
c
Appetite loss 61.7 (41.0) 45.8 (41.8) 15.8 (32.0) 0.007
Organ-speciﬁc questions from EORTC PAN 26
c
Have you been
itching?
46.6 (39.1) 23.3 (32.2) 23.3 (51.3) 0.01
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was
made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of overall
functioning
c Scale from 0 to 100; high scores represent more severe
Table 5 Scores from EORTC C30
a and selected questions from EORTC CR38 from 46 patients treated with colon stents
Before After Difference P value
Global health function
b 38.0 (24.8) 48.7 (23.7) 10.7 (24.5) 0.009
Symptom scales
a, c
Pain 49.3 (33.9) 28.4 (30.0) 20.9 (39.0) 0.001
Nausea /vomiting 29.4 (34.1) 13.8 (21.5) 15.6 (33.6) 0.003
Single items
c
Appetite loss 45.4 (40.8) 31.9 (35.4) 13.5 (45.4) 0.04
Constipation 53.9 (43.7) 24.8 (32.2) 29.1 (46.0) \0.001
Diarrhea 37.6 (37.2) 45.4 (33.6) -7.8 (45.7) 0.26
Organ-speciﬁc questions from EORTC CR38
c
Have you had abdominal pain? 53.6 (38.2) 32.6 (28.5) 21.0 (37.4) \0.001
Have you felt bloated? 67.4 (36.2) 27.5 (30.0) 40.0 (44.8) \0.001
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was made; no signiﬁcant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of overall functioning
c Scale from 0 to 100; high scores represent more severe symptoms
Table 6 Patient-reported symptomatic effect of stent treatment
Number of patients with clinical
effect on C1 symptoms
Number of patients with no
effect or worsening of symptoms
Esophageal stent 34 (81%) 8 (19%)
Gastroduodenal stent 16 (48%) 17 (52%)
Biliary stent 20 (50%) 20 (50%)
Colonic stent 33 (69%) 15 (31%)
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regularly did not beneﬁt from SEMS treatment and,
therefore, should have received alternative palliative
treatment. This might be due to the relatively low number
of patients included.
Seventy-six patients completed only the ﬁrst question-
naire. However, as shown in Fig. 1, only 27 patients failed
to complete the second questionnaire for unknown reasons.
It is possible that these patients did not experience the
expected effect of the stent treatment and that this lack of
data could represent a selection bias. However, we know
that these 27 patients did not differ in age, pretreatment
global health, or survival from the 162 repliers. Three of
these 27 patients experienced dysfunctional stents and
needed reinterventions during the ﬁrst 2 weeks, which
might have inﬂuenced their opinion of stent function. Three
patients experienced cholangitis and/or pancreatitis
immediately after biliary stenting but had functional stents.
For the remaining 21 of the 27 patients, there was not
sufﬁcient information in their medical records to explain
why they did not return their second questionnaire.
Conclusion
SEMS treatment is effective in relieving symptoms of
malignant GI and biliary obstruction, according to assess-
ment by both patients and physicians. This study demon-
strates a signiﬁcant difference in how the physicians and
patients evaluate treatment effects and thereby the impor-
tance of taking patient-reported outcomes into account
when evaluating clinical palliative interventions. Future
studies evaluating SEMS treatment should include pro-
spective assessment of patient-reported outcomes to
increase our knowledge about the efﬁcacy of this treatment.
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